Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 604-045-2 | CAS number: 137862-53-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Description of key information
No teratogenic effects and no effect on fertility could be observed in segment I (fertility and reproduction), segment II (Teratology) studies and segment III (perinatal and postnatal) studies in different species.
Cases have been reported that use of pharmaceutic active substances acting directly on the renin-angiotensin system like (test substance) during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury and can cause fetal and neonatal morbidity and even death to the developing fetus when administered to pregnant women.
Toxicity to reproduction: other studies
Additional information
Segment I (fertility and reproduction) and segment III (perinatal and postnatal) studies in rats and segment II (Teratology) studies in rats, mice and rabbits have been performed (Bradley, 1995, Expert Report on the Toxicological and Pharmacological Documentation).
In the segment I study, rats were treated with test substance doses of 10, 50 and 200 mg/kg bw/d via gavage for 90 days (males) or from day 14 to 20 (females). No effects on fertility and reproductive performance were observed in F0 and F1 generation. No effects on F1 development, especially on kidney development were noticed.
Segment II studies were performed in rats, rabbits and mice. Mice and rats were treated on days 6 through 15 with 60, 200 and 600 mg/kg bw/d of the test substance by gavage. No embryotoxic, fetotoxic and teratogenic effects were observed in both species. In rats, the maternal body weight gain was decreased at 200 and 600 mg/kg bw/d and fetal weights were reduced at 600 mg/kg bw/d.
In a range-finding study, rabbits were treated on days 6 through 18 with doses of 2.5, 15, 30, 45, 50 and 150 mg/kg bw/d. At 15 mg/kg bw/d and above, litter losses and deaths occurred. In the main study, rabbits were treated with test substance doses of 2, 5 and 10 mg/kg bw/d via gavage on days 6 through 18 or days 7 through 19. No teratogenicity occurred. An increased incidence of low fetal weights was observed. Fetotoxicity in rabbits at 5 mg/kg and above was characterized by litter loss and abortion and was closely associated with maternal toxicity.
In the segment III study, rats were treated with 60, 200 and 600 mg/kg bw/d by gavage on days 15 through 20. At 600 mg/kg bw/d, reduced maternal body weight gain and slightly reduced post natal F1 survival and development were observed. At 600 mg/kg bw/d, slightly reduced pup survival and development together with reduced maternal body weight gain was observed. No effects were observed on kidney development.
Cases have been reported that use of pharmaceutic active substances acting directly on the renin-angiotensin system like the test substance during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury and can cause fetal and neonatal morbidity and even death to the developing fetus when administered to pregnant women.
For precautionary reasons with regard to Responsible Care the substance has to be considered as toxic to Reproduction based on the criteria of the CLP Regulation (EC) No 1272(2008).
Justification for classification or non-classification
Because of the known "Class effect" of substances based on renin-angiotensin system and the adverse effect on the developing fetus the substance is classified as a Reproductive Substance Category 2
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.